These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

709 related items for PubMed ID: 19187902

  • 1. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial.
    Singh SN, Tang XC, Reda D, Singh BN.
    Heart Rhythm; 2009 Feb; 6(2):152-5. PubMed ID: 19187902
    [Abstract] [Full Text] [Related]

  • 2. [Impact of electrical shock waveform and paddle positions on efficacy of direct current cardioversion for atrial fibrillation].
    Stanaitiene G, Babarskiene RM.
    Medicina (Kaunas); 2008 Feb; 44(9):665-72. PubMed ID: 18971603
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of sequential antiarrhythmic treatment in sinus rhythm maintenance after successful electrocardioversion in patients with chronic non-valvular atrial fibrillation.
    Kosior D, Opolski G, Torbicki A.
    Med Sci Monit; 2001 Feb; 7(1):68-73. PubMed ID: 11208496
    [Abstract] [Full Text] [Related]

  • 4. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
    Joseph AP, Ward MR.
    Ann Emerg Med; 2000 Jul; 36(1):1-9. PubMed ID: 10874228
    [Abstract] [Full Text] [Related]

  • 5. Monophasic versus biphasic waveform shocks for atrial fibrillation cardioversion in patients with concomitant amiodarone therapy.
    Kawabata VS, Vianna CB, Moretti MA, Gonzalez MM, Ferreira JF, Timerman S, Cesar LA.
    Europace; 2007 Feb; 9(2):143-6. PubMed ID: 17272337
    [Abstract] [Full Text] [Related]

  • 6. Atrial fibrillation: rate control often better than rhythm control.
    Prescrire Int; 2004 Apr; 13(70):64-9. PubMed ID: 15148984
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned.
    Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA, Harcombe AA, Linker NJ, Stewart MJ, Davies A, de Belder MA.
    Am Heart J; 2006 Apr; 151(4):863.e1-6. PubMed ID: 16569550
    [Abstract] [Full Text] [Related]

  • 8. Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial.
    Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM.
    Card Electrophysiol Rev; 2003 Sep; 7(3):201-7. PubMed ID: 14739713
    [Abstract] [Full Text] [Related]

  • 9. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
    Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, Schwarz C, Lehner E, Strasser U, Lassnig E, Lamm G, Eber B, Study of Prevention of Postoperative Atrial Fibrillation.
    Am Heart J; 2004 Apr; 147(4):636-43. PubMed ID: 15077078
    [Abstract] [Full Text] [Related]

  • 10. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J.
    Am J Cardiol; 2003 Mar 20; 91(6A):15D-26D. PubMed ID: 12670638
    [Abstract] [Full Text] [Related]

  • 11. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries.
    Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM, GUSTO-III Investigators.
    Heart; 2002 Oct 20; 88(4):357-62. PubMed ID: 12231591
    [Abstract] [Full Text] [Related]

  • 12. External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.
    Kukendrarajah K, Ahmad M, Carrington M, Ioannou A, Taylor J, Razvi Y, Papageorgiou N, Mead GE, Nevis IF, D'Ascenzo F, Wilton SB, Lambiase PD, Morillo CA, Kwong JS, Providencia R.
    Cochrane Database Syst Rev; 2024 Jun 03; 6(6):CD013255. PubMed ID: 38828867
    [Abstract] [Full Text] [Related]

  • 13. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
    AFFIRM First Antiarrhythmic Drug Substudy Investigators.
    J Am Coll Cardiol; 2003 Jul 02; 42(1):20-9. PubMed ID: 12849654
    [Abstract] [Full Text] [Related]

  • 14. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM, Verma A, Talajic M, Nattel S, Dorian P, CCS Atrial Fibrillation Guidelines Committee.
    Can J Cardiol; 2011 Jul 02; 27(1):47-59. PubMed ID: 21329862
    [Abstract] [Full Text] [Related]

  • 15. Exercise capacity in atrial fibrillation: a substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T).
    Atwood JE, Myers JN, Tang XC, Reda DJ, Singh SN, Singh BN.
    Am Heart J; 2007 Apr 02; 153(4):566-72. PubMed ID: 17383295
    [Abstract] [Full Text] [Related]

  • 16. [Ambulatory electrocardioversion of atrial fibrillation by means of biphasic versus monophasic shock delivery. A prospective randomized study].
    Neumann T, Erdogan A, Reiner C, Siemon G, Kurzidim K, Berkowitsch A, Kuniss M, Sperzel J, Hamm CW, Pitschner HF.
    Z Kardiol; 2004 May 02; 93(5):381-7. PubMed ID: 15160273
    [Abstract] [Full Text] [Related]

  • 17. Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters.
    Biffi M, Boriani G, Bartolotti M, Bacchi Reggiani L, Zannoli R, Branzi A.
    Heart; 2002 May 02; 87(5):443-8. PubMed ID: 11997417
    [Abstract] [Full Text] [Related]

  • 18. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion.
    Kumar S, Sutherland F, Morton JB, Lee G, Morgan J, Wong J, Eccleston DE, Voukelatos J, Garg ML, Sparks PB.
    Heart Rhythm; 2012 Apr 02; 9(4):483-91. PubMed ID: 22120130
    [Abstract] [Full Text] [Related]

  • 19. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.
    Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G, Prevention of Atrial Fibrillation after Cardioversion Investigators.
    Eur Heart J; 2004 Aug 02; 25(16):1385-94. PubMed ID: 15302102
    [Abstract] [Full Text] [Related]

  • 20. One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
    Kim MH, Smith PJ, Jhaveri M, Lin J, Klingman D.
    Clin Ther; 2011 Nov 02; 33(11):1668-1681.e1. PubMed ID: 22108302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.